Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging progression-free survival (PFS) in advanced ALK-positive NSCLC patients who are treatment naïve.
Critère d'inclusion
- Advanced ALK positive non small cell lung cancer